Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy
- Conditions
- Interventions
- Drug: PEG-rhG-CSF, 100μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycleDrug: YPEG-rhG-CSF, 30μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycleDrug: YPEG-rhG-CSF, 20μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycleDrug: YPEG-rhG-CSF, 45μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle
- First Posted Date
- 2013-12-09
- Last Posted Date
- 2018-07-17
- Lead Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT02005458
- Locations
- 🇨🇳
Zhangzhou Municipal Hospital of Fujian Province, Zhangzhou, Fujian, China
🇨🇳Shanghai Changzheng Hospital, Shanghai, China
🇨🇳Shaaxi Provincial Tumor Hospital, Xi'an, Shaanxi, China
PK & PD Study of Pegylated rhEPO, and Evaluated Its Safety and Tolerability in Male Healthy Individual
- First Posted Date
- 2013-02-27
- Last Posted Date
- 2015-08-31
- Lead Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT01800305
- Locations
- 🇨🇳
302 Military Hospital of China, Beijing, China
Efficacy and Safety of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B
- First Posted Date
- 2013-01-03
- Last Posted Date
- 2015-08-31
- Lead Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
- Target Recruit Count
- 820
- Registration Number
- NCT01760122
- Locations
- 🇨🇳
Beijing Youan Hospital, Capital Medical University, Beijing, China
🇨🇳Xiangya Hospital, Central-south University, Changsha, China
🇨🇳Xiangya Second Hospital, Central-south University, Changsha, China
Efficacy and Safety Study of Peginterferon Alfa-2b in Chinese Chronic Hepatitis C Patients
- First Posted Date
- 2012-04-20
- Last Posted Date
- 2014-10-07
- Lead Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
- Target Recruit Count
- 770
- Registration Number
- NCT01581398
- Locations
- 🇨🇳
85 Militay Hospital, Shanghai, China
🇨🇳Huashan Hospital, Shanghai, China
🇨🇳Xiangya Hospital, Central-south University, Changsha, China
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Assessment of Ypeginterferon Alfa-2a in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2011-04-27
- Last Posted Date
- 2012-01-31
- Lead Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
- Target Recruit Count
- 39
- Registration Number
- NCT01343186
- Locations
- 🇨🇳
302 Military Hospital of China, Beijing, China
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Pegylated-Somatropin in Healthy Volunteers
- First Posted Date
- 2011-04-20
- Last Posted Date
- 2013-02-04
- Lead Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT01339182
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of YPEG-Filgrastim in Chemotherapy Patients
- First Posted Date
- 2010-11-10
- Last Posted Date
- 2013-02-04
- Lead Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT01238562
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China
Antifugal Effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) in Patients Post Allo-HSCT
- Conditions
- Interventions
- First Posted Date
- 2010-11-02
- Last Posted Date
- 2014-11-04
- Lead Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
- Target Recruit Count
- 206
- Registration Number
- NCT01232504
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China
Efficacy and Safety of Ypeginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B
- Conditions
- Interventions
- First Posted Date
- 2010-06-14
- Last Posted Date
- 2013-02-04
- Lead Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
- Target Recruit Count
- 205
- Registration Number
- NCT01143662
- Locations
- 🇨🇳
Tianjin Third Central Hospital, Tianjin, China
🇨🇳First Affiliated Hospital of Wenzhou Medical College, Wenzhou, China
🇨🇳Tangdu Hospital, Fourth Military Medical University, Xian, China
Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C
- Conditions
- Interventions
- First Posted Date
- 2010-06-10
- Last Posted Date
- 2013-02-04
- Lead Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
- Target Recruit Count
- 211
- Registration Number
- NCT01140997
- Locations
- 🇨🇳
302 Military Hospital, Beijing, China
🇨🇳Peking University People's Hospital, Beijing, China
🇨🇳Xiangya Second Hospital, Central-south University, Changsha, China